Heart Failure in Cardiomyopathies: A Position Paper from the Heart Failure Association of the European Society of Cardiology

Сердечная недостаточность при кардиомиопатиях: позиционный документ Ассоциации по сердечной недостаточности Европейского общества кардиологов
Giuseppe M.C. Rosano, Christian Eugen Mueller, Alida L.P. Caforio, Massimo Francesco Piepoli, Johann K Bauersachs, Jelena Čelutkienė, Tiny Jaarsma, Aleš Linhart, Gerasimos S Filippatos, Claudio Rapezzi, Yu. M. Lopatin, Ovidiu Dragomir Chioncel, Andrew J.S. Coats, Rudolf A. de Boer, Loreena Hill, Marco Metra, Wilfried Müllens, Frank Thomas Ruschitzka, Petar M Seferovic, Stefan D. Anker, Carsten Tschöpe, Davor Miličić, Stephan Burkhard Felix, Dimitrios T. Farmakis, Alexander Richard Lyon, Eloisa Arbustini, Ali Oto, Lars H. Lund, Michel Noutsias, Maurizio Volterrani, Arsen D. Ristić, Giuseppe Limongelli, Johannes Backs, Michael Arad, Tuvia Ben Gal, Brenda Moura, Milika Ašanin, Öztekin Oto, Marija M. Polovina, ELIAS J. GIALAFOS, Vladimir Kanjuh, Gordana Krljanać, Ružica Maksimović, Ivan Milinković, Siniša U. Pavlović, Hubert Seggewiß, Jelena P. Seferović
2019-04-16

cardiomyopathiesdilated cardiomyopathyheart failurehypertrophic cardiomyopathyrestrictive cardiomyopathy
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
1
Heart failure in cardiomyopathies has distinct epidemiology, pathophysiology, natural history, and treatment responses across DCM, HCM, and RCM.
2
In dilated cardiomyopathy, HFrEF is highly prevalent, the most frequent cause of death, and a major indication for heart transplantation despite improved treatment.
3
In hypertrophic cardiomyopathy, HFpEF affects most patients with obstructive disease and approximately 10% with non-obstructive disease; advanced HF is uncommon but carries poor prognosis.
4
In restrictive cardiomyopathy, HFpEF is common, whereas HFrEF develops later and is more frequent in amyloidosis or iron overload/haemochromatosis; HF predicts poor outcomes regardless of cause.
5
Mechanism-based and aetiology-specific treatments, including enzyme replacement, transthyretin stabilizers, immunoadsorption, and immunotherapy, may improve outcomes, but effective causal therapies remain unavailable for many cardiomyopathies.

Heart failure in patients with dilated, hypertrophic, and restrictive cardiomyopathies

The epidemiology, pathophysiology, natural history, therapeutic responses, and treatment strategies for heart failure in cardiomyopathies

Publication Details
Publication Date
2019-04-16
Journal
Publisher
ISSN
Cited by
417
Access Type
Author Information
Authors
Giuseppe M.C. Rosano
Christian Eugen Mueller
Alida L.P. Caforio
Massimo Francesco Piepoli
Johann K Bauersachs
Jelena Čelutkienė
Tiny Jaarsma
Aleš Linhart
Gerasimos S Filippatos
Claudio Rapezzi
Yu. M. Lopatin
Ovidiu Dragomir Chioncel
Andrew J.S. Coats
Rudolf A. de Boer
Loreena Hill
Marco Metra
Wilfried Müllens
Frank Thomas Ruschitzka
Petar M Seferovic
Stefan D. Anker
Carsten Tschöpe
Davor Miličić
Stephan Burkhard Felix
Dimitrios T. Farmakis
Alexander Richard Lyon
Eloisa Arbustini
Ali Oto
Lars H. Lund
Michel Noutsias
Maurizio Volterrani
Arsen D. Ristić
Giuseppe Limongelli
Johannes Backs
Michael Arad
Tuvia Ben Gal
Brenda Moura
Milika Ašanin
Öztekin Oto
Marija M. Polovina
ELIAS J. GIALAFOS
Vladimir Kanjuh
Gordana Krljanać
Ružica Maksimović
Ivan Milinković
Siniša U. Pavlović
Hubert Seggewiß
Jelena P. Seferović
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%